{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:03:30Z","timestamp":1765713810199},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.juro.2006.03.030","type":"journal-article","created":{"date-parts":[[2006,6,29]],"date-time":"2006-06-29T17:44:54Z","timestamp":1151603094000},"page":"439-449","source":"Crossref","is-referenced-by-count":39,"title":["Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era"],"prefix":"10.1097","volume":"176","author":[{"given":"Richard M.","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gunnell","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddie","family":"Hamdy","sequence":"additional","affiliation":[{"name":"Division of Clinical Sciences (South), University of Sheffield, Sheffield"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Neal","sequence":"additional","affiliation":[{"name":"Oncology Centre, University of Cambridge, Cambridge, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athene","family":"Lane","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Donovan","sequence":"additional","affiliation":[{"name":"Department of Social Medicine, University of Bristol, Bristol"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl","key":"10.1016\/j.juro.2006.03.030_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0959-8049(01)00267-2","article-title":"Cancer burden in the year 2000. The global picture","volume":"37","author":"Parkin","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.juro.2006.03.030_bib2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(94)92156-3","article-title":"Localised prostatic cancer","volume":"343","author":"Whitmore","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2006.03.030_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1056\/NEJMe048119","article-title":"Progress toward identifying aggressive prostate cancer","volume":"351","author":"Eisenberger","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2006.03.030_bib4","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S0140-6736(03)12890-5","article-title":"Screening for prostate cancer","volume":"361","author":"Frankel","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.juro.2006.03.030_bib5","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0022-5347(01)63572-9","article-title":"Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy","volume":"159","author":"Gerber","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1464-410X.2003.04669.x","article-title":"Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort","volume":"93","author":"El-Geneidy","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.03.030_bib7","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/JCO.2003.04.092","article-title":"Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era","volume":"21","author":"Carter","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2006.03.030_bib8","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/01.ju.0000094190.46523.b2","article-title":"Predictors of treatment after initial surveillance in men with prostate cancer","volume":"170","author":"Meng","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib9","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/S0022-5347(05)65657-1","article-title":"Conservative management of prostate cancer in the prostate specific antigen era","volume":"166","author":"Zietman","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1464-410x.1998.00523.x","article-title":"Prostate specific antigen velocity as a measure of the natural history of prostate cancer","volume":"81","author":"Nam","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.ju.0000113300.74132.8b","article-title":"Watchful waiting and factors predictive of secondary treatment of localized prostate cancer","volume":"171","author":"Wu","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.urology.2004.03.020","article-title":"Variations in PSA doubling time in patients with prostate cancer on \u201cwatchful waiting\u201d","volume":"64","author":"Ross","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.030_bib13","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/01.ju.0000118224.54949.78","article-title":"An analysis of men with clinically localized prostate cancer who deferred definitive therapy","volume":"171","author":"Patel","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib14","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1097\/01.ju.0000097124.21878.6b","article-title":"Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?","volume":"170","author":"Khan","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib15","first-page":"236","article-title":"Clinical outcome of patients with stage T1a prostate cancer","volume":"66","author":"Chen","year":"2003","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.juro.2006.03.030_bib16","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","article-title":"Feasibility study","volume":"167","author":"Choo","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib17","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0090-4295(02)01526-1","article-title":"Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer","volume":"59","author":"Stephenson","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.030_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0302-2838(01)00020-3","article-title":"Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men","volume":"41","author":"Kakehi","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib19","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S0090-4295(01)01358-9","article-title":"Molecular prediction of progression in patients with conservatively managed prostate cancer","volume":"58","author":"McIntyre","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.030_bib20","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1464-4096.2001.01558.x","article-title":"The role of volume-weighted mean nuclear volume in predicting tumour biology and clinical behaviour in patients with prostate cancer undergoing watchful waiting","volume":"88","author":"Arai","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.03.030_bib21","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1464-410x.2000.00569.x","article-title":"Deferred treatment of localized prostate cancer in the elderly","volume":"85","author":"Neulander","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.03.030_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z","article-title":"Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma","volume":"82","author":"McLaren","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.03.030_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01300184","article-title":"Expectant management as an option for men with stage T1c prostate cancer","volume":"15","author":"Mohler","year":"1997","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib24","first-page":"157","article-title":"Tumour markers in patients on deferred treatment","volume":"23","author":"Schmid","year":"1995","journal-title":"Cancer Surv"},{"key":"10.1016\/j.juro.2006.03.030_bib25","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0022-5347(01)66877-0","article-title":"Serial prostate specific antigen measurements and progression in untreated confined (stages T0 to 3NxM0, grades 1 to 3) carcinoma of the prostate","volume":"154","author":"Bangma","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib26","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S0022-5347(05)65654-6","article-title":"Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease","volume":"166","author":"Epstein","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0022-5347(05)65271-8","article-title":"Expectant management of nonpalpable prostate cancer with curative intent","volume":"167","author":"Carter","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib28","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1464-410X.2004.04926.x","article-title":"Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma","volume":"94","author":"Choo","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.03.030_bib29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1046\/j.1464-410X.2002.02737.x","article-title":"The role of serial free\/total prostate-specific antigen ratios in a watchful observation protocol for men with localized prostate cancer","volume":"89","author":"Do","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2006.03.030_bib30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.10443","article-title":"The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma","volume":"94","author":"Vollmer","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2006.03.030_bib31","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jama.280.11.975","article-title":"Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer","volume":"280","author":"Albertsen","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2006.03.030_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0090-4295(97)00178-7","article-title":"Clinical significance of repeat sextant biopsies in prostate cancer patients","volume":"49","author":"Stroumbakis","year":"1997","journal-title":"Urology, suppl."},{"key":"10.1016\/j.juro.2006.03.030_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0090-4295(93)90362-E","article-title":"Relationship between changes in prostate-specific antigen and prognosis of prostate cancer","volume":"42","author":"Cadeddu","year":"1993","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.030_bib34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S0022-5347(17)41174-8","article-title":"Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients","volume":"141","author":"Stamey","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0022-5347(17)32375-3","article-title":"Natural history of changes in prostate specific antigen in early stage prostate cancer","volume":"152","author":"Pearson","year":"1994","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa032975","article-title":"Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy","volume":"351","author":"D\u2019Amico","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.juro.2006.03.030_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0090-4295(96)00629-2","article-title":"Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis","volume":"49","author":"Carter","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.juro.2006.03.030_bib38","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1097\/01.ju.0000091641.34674.11","article-title":"Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer","volume":"170","author":"Harlan","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib39","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bjc.1998.605","article-title":"Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting","volume":"78","author":"Borre","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2006.03.030_bib40","first-page":"1882","article-title":"Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting","volume":"6","author":"Borre","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2006.03.030_bib41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0022-5347(05)67288-6","article-title":"p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting","volume":"164","author":"Borre","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib42","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/00005392-199805000-00054","article-title":"Tumor cell proliferation and survival in patients with prostate cancer followed expectantly","volume":"159","author":"Borre","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/(SICI)1097-0045(19980901)36:4<244::AID-PROS5>3.0.CO;2-F","article-title":"DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure","volume":"36","author":"Borre","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.juro.2006.03.030_bib44","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0022-5347(01)64281-2","article-title":"Genetic alterations in incidentally diagnosed, transitional zone prostate cancer","volume":"158","author":"Crundwell","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2006.03.030_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L","article-title":"c-erbB-2 oncoprotein","volume":"30","author":"Arai","year":"1997","journal-title":"Prostate"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706007889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534706007889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2006.03.030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:15:08Z","timestamp":1651194908000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2006.03.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1016\/j.juro.2006.03.030"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2006.03.030","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}